PF 055Alternative Names: PF-055
Latest Information Update: 19 Oct 2016
At a glance
- Originator Renaissance Pharma
- Developer Mylan
- Class Antiparasitics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Scabies
Most Recent Events
- 25 Mar 2014 Phase-II clinical trials in Scabies (In infants, children, adolescents and adults) in USA (Topical)